학술논문
No Impact of Eight NTRK2Genetic Polymorphisms On 6-Month Antidepressant Efficacy in Depressed Patients
Document Type
Article
Author
Source
Pharmacogenomics; March 2017, Vol. 18 Issue: 4 p349-357, 9p
Subject
Language
ISSN
14622416; 17448042
Abstract
Aim:NTRK2 is the main receptor of the brain derived neurotrophic factor, which is involved in antidepressant efficacy. We assessed the impact of eight NTRK2SNPs pertaining to response and remission after antidepressant treatment in depressed patients. Patients & methods:In a naturalistic study, 569 patients with a major depressive episode requiring a new antidepressant treatment were genotyped for eight NTRK2SNPs (rs1187352, rs1439050, rs1778933 rs2289656, rs2289657, rs2289658, rs3824519, rs56142442) and prospectively assessed for response and remission after 6 months of treatment. Results:No association was shown between the NTRK2SNPs and response/remission. Conclusion:There is no benefit to assess these eight TRKBSNPs to predict response/remission after antidepressant treatment in depressed patients.